We have demonstrated that AURKA promotes activating phosphorylation of YAP1 at Ser397, leading to the primary cetuximab-resistant phenotype in preclinical models of RAS/RAF wild-type CRC. This evidence concerns the gene YAP1 and colorectal carcinoma.